[A25-108] Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V

Last updated 12.11.2025

Project no.:
A25-108

Commission:
Commission awarded on 18.08.2025 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission work started

Department/Division:
Drug Assessment

Topic:
Cancer

Project no.	Title	Status
A25-40	Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V	Commission completed
A24-114	Daratumumab (newly diagnosed multiple myeloma, suitable for autologous stem cell transplant) – Benefit assessment according to §35a Social Code Book V	Commission completed
A23-127	Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V	Commission completed
A22-40	Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)	Commission completed
A21-126	Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)	Commission completed
A21-101	Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A21-100	Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V	Commission completed
A20-15	Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V	Commission completed
A20-14	Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A18-66	Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V	Commission completed
A17-40	Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V	Commission completed
G16-02	Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V	Commission completed
A25-109	Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V	Commission work started

Contact

Press contact

+49 221 356850

presse@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form